New Report Estimates That South Africa Pharmaceuticals and Healthcare Market Was...

New Report Estimates That South Africa Pharmaceuticals and Healthcare Market Was Worth US$3.03bn in 2007 and Should Reach US$4.41bn By 2012

DUBLIN, Ireland--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/research/b0eecf/south_africa_pharm)
has announced the addition of the "South Africa Pharmaceuticals and
Healthcare Report Q3 2008" report to their offering.

South Africa Pharmaceuticals and Healthcare Report provides
independent forecasts and competitive intelligence on South Africa's
pharmaceuticals and healthcare industry.

South Africa's pharmaceutical and healthcare markets are going
through a period of regulatory upheaval. On the approvals front, a new
South African Health Products Regulatory authority has been proposed
to replace the Medicines Control Council (MCC); on the pricing front,
the government has drafted plans to more strictly regulate private
hospital prices; and on the business environment front, the South
African Healthcare Charter sets out guidelines for Black Economic
Empowerment (BEE). Despite the upheavals, South Africa's
pharmaceutical market remains one of the most promising in Africa. BMI
estimates that the market was worth US$3.03bn in 2007 and it should
reach US$4.41bn by 2012. The drug market should continue to grow head
of inflation despite controls limiting pharmaceutical price rises,
indicating that there will be significant volume growth in the market.

This view is reflected in our updated Business Environment
Rankings for Q308. South Africa remains in third position out of 13
countries surveyed in the Middle East & Africa thanks to its large
market and strong growth prospects. South Africa's score is held back
by a slow approvals process. Under the present system it can take
24-36 months to register a pharmaceutical. However, the proposed
regulatory overhaul aims to cut this to 12 months for a new chemical
entity (NCE).

The local pharmaceutical industry is relatively strong in spite of
regulatory challenges and competition from multinationals. Parent
company Tiger Brands continues to hold plans to spin off its
pharmaceutical interest Adcock Ingram through a separate listing on
the Johannesburg stock exchange (JSE). However, this has been delayed
by Adcock Ingram's naming in an investigation by the Competition
Commission into allegations of price fixing in government hospital
tenders.

The results of South Africa's new HIV/AIDS drug tender are due to
be announced in Q308. The main criteria for winning a slice of the
contract remains price. However, a local manufacturing presence and
black empowerment policy will also play a part in the decision.

Healthcare funding remains a key issue in South Africa. Despite
significant increases in the Department of Health's budget (expected
to be 10% a year to 2010), the affordability of the fight against
HIV/AIDS remains a concern. Meanwhile, private healthcare costs are
expected to be more strictly regulated as the government looks to
encourage more people into the private health insurance market.

Key Topics Covered:

"Executive Summary

South Africa Political SWOT

South Africa Economic SWOT

South Africa Business Environment SWOT

Pharmaceutical Business Environment Ratings

Table: Pharmaceutical Business Environment Ratings

Limits To Potential Returns

Risks To Realisation Of Returns

South Africa - Market Summary

Regulatory Regime

Table: South Africa Drug Classification System (Section 22A Of
Medicines And Reated Substance Act 101 Of 1965)

Recent Regulatory Developments

Proposed Scope Of the South African Health products Regulatory

Intellectual Property Environment

Compulsory Licensing

Counterfeit Activity

Pricing System

Reimbursement System

Recent Pricing And Reimbursement Developments

Table: Companies Involved In South Africa's February 2008 Price
Fixing Scandal

Industry Developments

Epidemiology

Table: Leading Causes Of Disease In Africa, 2002

HIV/AIDS

Tuberculosis

Healthcare Sector

Recent Healthcare Sector Developments

Health Insurance

Government Health Insurance

Recent Insurance Industry Developments

Pharmaceutical Sector

Table: PIASA Membership

ARV Manufacturing and Government Tenders

Table: Results Of South Africa's HIV/AIDS Drug Tender, March 2005

Domestic Company Developments

Key Facts: Strategic Partnership Between Strides Arcolab And Aspen
Pharmacare

Foreign Company Developments

Retail Pharmacy Sector

Research And Development Sector

AIDS/HIV Research

Vaccines

Traditional African Medicine

Medical Devices

Table: South African Customs Classification Of Medical Devices

Regional Developments in Medical Devices Sector

Table: Aims Of PEPFAR-BD Partnership

Industry Forecast Scenario

Overall Market Forecast

Table: Drug Expenditure And Prescription Market Indicators (US$mn
unless otherwise stated)

Key Growth Factors - Industry

Table: Health Expenditure Indicators, 2006-2012

Key Growth Factors - Macroeconomic

Table: South Africa - Economic Activity

Patented Market Forecast

Table: South Africa's Prescription Drug Market Forecast Indicators
(US$mn unless otherwise stated)

Generics Market Forecast

Table: South Africa's Generic Drug Market, 2006-2012

OTC Market Forecast

Table: South Africa's OTC Drug Market Indicators, 2006-2012 (US$mn
unless otherwise stated)

Medical Device Forecast

Table: South Africa's Medical Device Market, 2005-2012 (US$mn
unless otherwise stated)

Export/Import Forecasts

Table: South Africa's Export And Import Trade Indicators,
2006-2012 (US$mn)

Other Healthcare Data

Table: General Healthcare Indicators, 2006-2012

Key Risks To BMI's Forecast Scenario

Competitive Landscape

Table: Top 10 Drugmakers In South Africa, 2006

Company Monitor

Leading Foreign Companies

Sanofi-Aventis

Pfizer

Roche

GlaxoSmithKline

Merck & Co

Leading Indigenous Manufacturers

Aspen Pharmacare

Adcock Ingram

Enaleni Pharmaceuticals

BMI Forecast Modelling

How We Generate Our Pharmaceutical Industry Forecasts

Pharmaceutical Business Environment Ratings Methodology

Ratings Overview

Table: Pharmaceutical Business Environment Indicators

Weighting

Table: Weighting Of Components

Sources

Companies Mentioned:

- Sanofi-Aventis

- Pfizer

- Roche

- GlaxoSmithKline

- Merck & Co

- Aspen Pharmacare

- Adcock Ingram

- Enaleni Pharmaceuticals

For more information visit
http://www.researchandmarkets.com/research/b0eecf/south_africa_pharm

Research and Markets
Laura Wood
Senior Manager
press@researchandmarkets.com
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716

Copyright Business Wire 2008